298 related articles for article (PubMed ID: 28942143)
41. MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene.
Ohuchida K; Mizumoto K; Lin C; Yamaguchi H; Ohtsuka T; Sato N; Toma H; Nakamura M; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2012 Jul; 19(7):2394-402. PubMed ID: 22407312
[TBL] [Abstract][Full Text] [Related]
42. Zebrafish reporter lines reveal in vivo signaling pathway activities involved in pancreatic cancer.
Schiavone M; Rampazzo E; Casari A; Battilana G; Persano L; Moro E; Liu S; Leach SD; Tiso N; Argenton F
Dis Model Mech; 2014 Jul; 7(7):883-94. PubMed ID: 24878567
[TBL] [Abstract][Full Text] [Related]
43. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
44. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
45. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
46. Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer.
Mameishvili E; Serafimidis I; Iwaszkiewicz S; Lesche M; Reinhardt S; Bölicke N; Büttner M; Stellas D; Papadimitropoulou A; Szabolcs M; Anastassiadis K; Dahl A; Theis F; Efstratiadis A; Gavalas A
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20679-20688. PubMed ID: 31548432
[TBL] [Abstract][Full Text] [Related]
47. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis.
Tu MJ; Pan YZ; Qiu JX; Kim EJ; Yu AM
Oncotarget; 2016 Jul; 7(29):45547-45561. PubMed ID: 27322206
[TBL] [Abstract][Full Text] [Related]
49. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
50. Loss of Pancreatic E-Cadherin Causes Pancreatitis-Like Changes and Contributes to Carcinogenesis.
Kaneta Y; Sato T; Hikiba Y; Sugimori M; Sue S; Kaneko H; Irie K; Sasaki T; Kondo M; Chuma M; Shibata W; Maeda S
Cell Mol Gastroenterol Hepatol; 2020; 9(1):105-119. PubMed ID: 31526907
[TBL] [Abstract][Full Text] [Related]
51. Proteasome activity is required for the initiation of precancerous pancreatic lesions.
Furuyama T; Tanaka S; Shimada S; Akiyama Y; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Fukamachi H; Arii S; Kawaguchi Y; Tanabe M
Sci Rep; 2016 May; 6():27044. PubMed ID: 27244456
[TBL] [Abstract][Full Text] [Related]
52. miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.
Neault M; Mallette FA; Richard S
Cell Rep; 2016 Mar; 14(8):1966-78. PubMed ID: 26904954
[TBL] [Abstract][Full Text] [Related]
53. In vivo reprogramming drives Kras-induced cancer development.
Shibata H; Komura S; Yamada Y; Sankoda N; Tanaka A; Ukai T; Kabata M; Sakurai S; Kuze B; Woltjen K; Haga H; Ito Y; Kawaguchi Y; Yamamoto T; Yamada Y
Nat Commun; 2018 May; 9(1):2081. PubMed ID: 29802314
[TBL] [Abstract][Full Text] [Related]
54. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.
Tran PT; Shroff EH; Burns TF; Thiyagarajan S; Das ST; Zabuawala T; Chen J; Cho YJ; Luong R; Tamayo P; Salih T; Aziz K; Adam SJ; Vicent S; Nielsen CH; Withofs N; Sweet-Cordero A; Gambhir SS; Rudin CM; Felsher DW
PLoS Genet; 2012; 8(5):e1002650. PubMed ID: 22654667
[TBL] [Abstract][Full Text] [Related]
55. p16
Al-Khalaf HH; Aboussekhra A
Mol Carcinog; 2017 Mar; 56(3):985-999. PubMed ID: 27596953
[TBL] [Abstract][Full Text] [Related]
56. Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1.
Kent OA; Mendell JT; Rottapel R
Mol Cancer Res; 2016 Mar; 14(3):267-77. PubMed ID: 26747707
[TBL] [Abstract][Full Text] [Related]
57. MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A.
Wang N; Zhou Y; Zheng L; Li H
Gynecol Oncol; 2014 Jul; 134(1):129-37. PubMed ID: 24793973
[TBL] [Abstract][Full Text] [Related]
58. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer.
Zhao G; Qin Q; Zhang J; Liu Y; Deng S; Liu L; Wang B; Tian K; Wang C
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S301-11. PubMed ID: 22552606
[TBL] [Abstract][Full Text] [Related]
59. [Pathogenesis of pancreatic carcinoma].
Schmid RM
Z Gastroenterol; 2002 Dec; 40 Suppl 2():58-61. PubMed ID: 12467012
[No Abstract] [Full Text] [Related]
60. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
Rachagani S; Macha MA; Menning MS; Dey P; Pai P; Smith LM; Mo YY; Batra SK
Oncotarget; 2015 Nov; 6(37):40295-309. PubMed ID: 26516699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
